Love of my life - best day!

Health tech founders have truly no idea how many AI solutions health systems are being pitched right now. It's approaching nearly a full time job just fielding the emails. Also this is literally day 2 for me at a health system.

70% of all digital health pilots fail before implementation.

🧬 This Austin Bio & Health Roundup covers the last few weeks, with summer and vacations slowing me down, but not the ecosystem. 🧬 💰 Funding & Capital Signals @GametoGen, a biotech developing stem cell-based therapies, raised $44M Series C to complete its Phase 3 infertility

Innovating in #HealthTech means balancing clinical, technical, and regulatory needs, often at the same time. Which core area is your biggest challenge?

🚨 8 in 10 healthtech startups fail. Not for lack of ideas—but because execution stalls without the right expertise.* Every day counts. Miss a market window and confidence (and capital) erodes fast. That’s why we built Health Expert Hourly → on-demand, 1:1 sessions with vetted

#AI in healthcare is at a transformational shift. Epic just announced major AI capabilities: streamlining clinician documentation, optimizing revenue cycle management, and enhancing patient engagement. They also unveiled Cosmos, a predictive engine powered by 300M+ patient

With ⁦⁦@DivaBiotech⁩ in Egypt, enjoying the South Med

Yesterday a physician who is in a CMO role and who I respect highly said this: “Most physicians know medicine but don’t understand the business of healthcare” Agree? Disagree? Discuss

Lord, grant me the delusional optimism of a founder who believes payers will reimburse a 10,000-biomarker wellness panel because it might help someone live to 130. He also thinks it’s a medical diagnostic—doctors just don’t know it yet. Make it make sense.

Anne Wojcicki to buy back 23andMe and its data for $305 million

In a new twist to the 23andme story....... 23andMe founder says Fortune 500 company backs new buyout offer

My Hot Take: The more a healthtech founder is in the press, the less likely their product has, you know… actual evidence. It’s a statistically significant inverse correlation—and yes, we ran the regression

Wow. Regeneron is acquiring the remains of 23andMe for $256M in a bankruptcy auction. The value that 23andMe built all lies in the Data. 23andMe spent years building one of the largest, most genotype-phenotype-linked datasets in the world. That’s gold for any pharma company

Wow!! Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million | Reuters

Lord, give me the confidence to pitch investors like Billy Evans—launching Theranos 2.0 while his wife is still serving time for Theranos 1.0.

Lord, give me the confidence of a tech bro building a digital therapeutic without a clinician, a regulatory plan, or a clue.

Proud mama moment: tonight, my 10 year old son was watching Shark Tank and he asked me how do sharks get to invest in multiple similar businesses without having a conflict of interest? I asked how do you know what conflict of interest is - he said I learned from listening to you.

If we thought vendor fatigue in healthcare was bad before, it's going to get 1000 times worse because of AI. Anyone can build a product or an app quickly now and they will be flooding to the gates of the health system leaders and the payers way before they're ready.

At a conference and heard a health system exec synthesize how they consider adoption of new health innovations - cost - quality - outcomes - a vision of why

The 23andMe Special Committee released news today indicating their plan to take the company through the Chapter 11 process.   While I am disappointed that we have come to this conclusion and my bid was rejected, I am supportive of the company and I intend to be a bidder.   I have